• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
QRX
Click for more information
0.00% 2.8¢

QRXPHARMA LTD - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
QRXCeasing to be a substantial holder04/06/12
QRXQRxPharma Granted Additional US Patent on MoxDuoPRICE SENSITIVE23/05/12
QRXAppendix 3B - Exercise of Stock Options21/05/12
QRXUS Commercialisation Partner Actavis to be acquired byWatson26/04/12
QRXAppendix 3B - Exercise of Stock Options17/04/12
QRXAppendix 3B - Option Issue17/04/12
QRXAppendix 4C - Quarter Ended 31 March 2012PRICE SENSITIVE16/04/12
QRXSuccessful Completion of Phase 1 Studies for MoxDuo CRPRICE SENSITIVE11/04/12
QRXAppendix 3B - Exercise of Stock Options27/03/12
QRXQRxPharma Signs License and Option Agreement with ActavisPRICE SENSITIVE19/03/12
QRXInvestor Presentation Update - March 201206/03/12
QRXQRxPharma Presents at Cowen Health Care Live Audio Webcast02/03/12
QRXAppendix 3B - Exercise of Stock Options01/03/12
QRXHalf Yearly Report and Accounts - 31 December 2011PRICE SENSITIVE24/02/12
QRXDr. Edward Rudnic Joins QRxPharma as Chief Operating Officer14/02/12
QRXAppendix 3B - Exercise of Stock Options07/02/12
QRXAppendix 4C - Quarter Ended 31 December 2011PRICE SENSITIVE30/01/12
QRXAppendix 3B - Option Issue27/01/12
QRXAppendix 3B - Exercise of Stock Options27/01/12
QRXChange in substantial holding23/01/12
QRXChange in substantial holding23/01/12
QRXChange in substantial holding23/01/12
QRXChange in substantial holding23/01/12
QRXInvestor Presentation Update - January 201210/01/12
QRXChange of Director's Interest Notice - John Holaday30/12/11
PDL +Change in substantial holding from BTT28/12/11
QRX +Change of Interest from WBC28/12/11
QRXAppendix 3B - Exercise of Stock Options22/12/11
QRXQRxPharma CEO discusses Strategic Partnership with Actavis21/12/11
QRXQRxPharma Announces Strategic Partnership with ActavisPRICE SENSITIVE21/12/11
QRXTrading Halt Request20/12/11
QRXTrading HaltPRICE SENSITIVE20/12/11
QRXChange in substantial holding x 429/11/11
QRXChange of Director's Interest Notice - John Holaday22/11/11
QRXAppendix 3B - Option Issue18/11/11
QRXResults of 2011 Annual General Meeting16/11/11
QRXChairman's and Managing Director's Addresses to Shareholders16/11/11
QRXPDUFA Target Date for FDA Action on MoxDuo IR NDA GrantedPRICE SENSITIVE08/11/11
QRXAppendix 3B - Exercise of Stock Options04/11/11
QRXAppendix 4C - Quarter Ended 30 September 2011PRICE SENSITIVE27/10/11
QRXAppendix 3B - Option Issue17/10/11
QRX2011 Notice of Annual General Meeting and Proxy Form14/10/11
QRXAppendix 3B - Exercise of Stock Options28/09/11
QRXAnnual Report to Shareholders - 201127/09/11
QRXChange in substantial holding20/09/11
QRXBecoming a substantial holder07/09/11
QRXChange of Director's Interest Notice - Peter Farrell01/09/11
QRXChange of Director's Interest Notice - Gary Pace01/09/11
QRXChange of Director's Interest Notice - Michael Quinn01/09/11
QRXChange of Director's Interest Notice - Peter Campbell01/09/11
QRXAppendix 3B - Rights Issue30/08/11
QRXNon-renounceable Rights Issue Despatch of Holding Statements30/08/11
QRXQRxPharma Completes NDA Submission for MoxDuo IRPRICE SENSITIVE25/08/11
QRXNon-renounceable Rights Issue Notice of under subscriptions25/08/11
QRXASX/ Media Release - Preliminary Final Report 30 June 201118/08/11
QRXPreliminary Final Report - 30 June 2011PRICE SENSITIVE18/08/11
QRXCorporate Update and Rights Issue closing 22 August 201115/08/11
QRXChange of Director's Interest Notice - Michael Quinn12/08/11
QRXCorrection Web Address - CEO discussion on Boardroom Radio10/08/11
QRXCEO on Recent Milestones and Rights Issue - Boardroom Radio10/08/11
QRXNotice of Despatch of Rights Issue Documents to Shareholders08/08/11
QRXRights Issue - Notice to Ineligible Shareholders08/08/11
QRXRights Issue - Letter to U.S. Eligible Shareholders08/08/11
QRXAppendix 3B - Exercise of Stock Options02/08/11
QRXAppendix 4C - Quarter Ended 30 June 2011PRICE SENSITIVE28/07/11
QRXNotification Section 708A(5)(e) Corporations Act27/07/11
QRXQRxPharma Rights Issue - Entitlement and Acceptance Form22/07/11
QRXNon-Renounceable Rights Issue - Letter to Shareholders22/07/11
QRXNon-Renounceable Rights Issue - Letter to Option Holders22/07/11
QRXQRxPharma Rights Issue Booklet22/07/11
QRXNotification Section 708AA(2)(f) Corporations Act22/07/11
QRXAppendix 3B - Placement and Rights Issue22/07/11
QRXQRxPharma Announces A$35 Million Capital RaisingPRICE SENSITIVE22/07/11
QRXInvestor Update and Capital Raising - 20 July 201120/07/11
QRXTrading HaltPRICE SENSITIVE20/07/11
QRXQRxPharma Announces NDA Filing for MoxDuo IRPRICE SENSITIVE18/07/11
QRXAppendix 3B - Option Issue13/07/11
QRXAdditional Data on MoxDuo IR Comparative Safety StudyPRICE SENSITIVE29/06/11
QRXInvestor Presentation Update - June 201120/06/11
QRXCEO discusses Comparative Safety Study on Boardroom Radio15/06/11
QRXSuccessful Completion MoxDuo IR Comparative Safety StudyPRICE SENSITIVE14/06/11
QRXPresentation of Clinical Data on MoxDuoTrials at APS Meeting17/05/11
QRXAppendix 3B - Exercise of Stock Options13/05/11
QRXAppendix 4C - Quarterly Report 31 March 2011PRICE SENSITIVE28/04/11
QRXEnrolment of MoxDuo IR Comparative Safety Study CompletedPRICE SENSITIVE27/04/11
QRXUSPTO Issues QRxPharma a New Patent for MoxDuo IRPRICE SENSITIVE14/04/11
QRXChange in substantial holding08/04/11
QRXChange in substantial holding07/04/11
QRXQRxPharma on Track to File New Drug Application Mid-YearPRICE SENSITIVE28/03/11
QRXCeasing to be a substantial holder16/03/11
ACL +SandP Announces March SP/ASX Rebalance04/03/11
QRXHalf Yearly Report and Accounts -31 December 2010PRICE SENSITIVE21/02/11
QRXInvestor Presentation Update - February 201121/02/11
QRXSuccessful Completion Third Pivotal MoxDuo IR Phase 3PRICE SENSITIVE21/02/11
QRXAppendix 4C - 31 December 2010PRICE SENSITIVE27/01/11
QRXInitiation of Phase 3 Comparative Safety Study of MoxDuo IRPRICE SENSITIVE24/01/11
QRXAppendix 3B - Option Issue06/01/11
QRXQRxPharma Securities Trading Policy31/12/10
QRXEnrolment of Pivotal MoxDuo IR Phase 3 Study CompletedPRICE SENSITIVE06/12/10
QRXChange of Director's Interest Notice - Peter Campbell26/11/10
QRXCeasing to be a substantial holder
04/06/12
QRXQRxPharma Granted Additional US Patent on MoxDuo
23/05/12PRICE SENSITIVE
QRXAppendix 3B - Exercise of Stock Options
21/05/12
QRXUS Commercialisation Partner Actavis to be acquired byWatson
26/04/12
QRXAppendix 3B - Exercise of Stock Options
17/04/12
QRXAppendix 3B - Option Issue
17/04/12
QRXAppendix 4C - Quarter Ended 31 March 2012
16/04/12PRICE SENSITIVE
QRXSuccessful Completion of Phase 1 Studies for MoxDuo CR
11/04/12PRICE SENSITIVE
QRXAppendix 3B - Exercise of Stock Options
27/03/12
QRXQRxPharma Signs License and Option Agreement with Actavis
19/03/12PRICE SENSITIVE
QRXInvestor Presentation Update - March 2012
06/03/12
QRXQRxPharma Presents at Cowen Health Care Live Audio Webcast
02/03/12
QRXAppendix 3B - Exercise of Stock Options
01/03/12
QRXHalf Yearly Report and Accounts - 31 December 2011
24/02/12PRICE SENSITIVE
QRXDr. Edward Rudnic Joins QRxPharma as Chief Operating Officer
14/02/12
QRXAppendix 3B - Exercise of Stock Options
07/02/12
QRXAppendix 4C - Quarter Ended 31 December 2011
30/01/12PRICE SENSITIVE
QRXAppendix 3B - Option Issue
27/01/12
QRXAppendix 3B - Exercise of Stock Options
27/01/12
QRXChange in substantial holding
23/01/12
QRXChange in substantial holding
23/01/12
QRXChange in substantial holding
23/01/12
QRXChange in substantial holding
23/01/12
QRXInvestor Presentation Update - January 2012
10/01/12
QRXChange of Director's Interest Notice - John Holaday
30/12/11
PDL +Change in substantial holding from BTT
28/12/11
QRX +Change of Interest from WBC
28/12/11
QRXAppendix 3B - Exercise of Stock Options
22/12/11
QRXQRxPharma CEO discusses Strategic Partnership with Actavis
21/12/11
QRXQRxPharma Announces Strategic Partnership with Actavis
21/12/11PRICE SENSITIVE
QRXTrading Halt Request
20/12/11
QRXTrading Halt
20/12/11PRICE SENSITIVE
QRXChange in substantial holding x 4
29/11/11
QRXChange of Director's Interest Notice - John Holaday
22/11/11
QRXAppendix 3B - Option Issue
18/11/11
QRXResults of 2011 Annual General Meeting
16/11/11
QRXChairman's and Managing Director's Addresses to Shareholders
16/11/11
QRXPDUFA Target Date for FDA Action on MoxDuo IR NDA Granted
08/11/11PRICE SENSITIVE
QRXAppendix 3B - Exercise of Stock Options
04/11/11
QRXAppendix 4C - Quarter Ended 30 September 2011
27/10/11PRICE SENSITIVE
QRXAppendix 3B - Option Issue
17/10/11
QRX2011 Notice of Annual General Meeting and Proxy Form
14/10/11
QRXAppendix 3B - Exercise of Stock Options
28/09/11
QRXAnnual Report to Shareholders - 2011
27/09/11
QRXChange in substantial holding
20/09/11
QRXBecoming a substantial holder
07/09/11
QRXChange of Director's Interest Notice - Peter Farrell
01/09/11
QRXChange of Director's Interest Notice - Gary Pace
01/09/11
QRXChange of Director's Interest Notice - Michael Quinn
01/09/11
QRXChange of Director's Interest Notice - Peter Campbell
01/09/11
QRXAppendix 3B - Rights Issue
30/08/11
QRXNon-renounceable Rights Issue Despatch of Holding Statements
30/08/11
QRXQRxPharma Completes NDA Submission for MoxDuo IR
25/08/11PRICE SENSITIVE
QRXNon-renounceable Rights Issue Notice of under subscriptions
25/08/11
QRXASX/ Media Release - Preliminary Final Report 30 June 2011
18/08/11
QRXPreliminary Final Report - 30 June 2011
18/08/11PRICE SENSITIVE
QRXCorporate Update and Rights Issue closing 22 August 2011
15/08/11
QRXChange of Director's Interest Notice - Michael Quinn
12/08/11
QRXCorrection Web Address - CEO discussion on Boardroom Radio
10/08/11
QRXCEO on Recent Milestones and Rights Issue - Boardroom Radio
10/08/11
QRXNotice of Despatch of Rights Issue Documents to Shareholders
08/08/11
QRXRights Issue - Notice to Ineligible Shareholders
08/08/11
QRXRights Issue - Letter to U.S. Eligible Shareholders
08/08/11
QRXAppendix 3B - Exercise of Stock Options
02/08/11
QRXAppendix 4C - Quarter Ended 30 June 2011
28/07/11PRICE SENSITIVE
QRXNotification Section 708A(5)(e) Corporations Act
27/07/11
QRXQRxPharma Rights Issue - Entitlement and Acceptance Form
22/07/11
QRXNon-Renounceable Rights Issue - Letter to Shareholders
22/07/11
QRXNon-Renounceable Rights Issue - Letter to Option Holders
22/07/11
QRXQRxPharma Rights Issue Booklet
22/07/11
QRXNotification Section 708AA(2)(f) Corporations Act
22/07/11
QRXAppendix 3B - Placement and Rights Issue
22/07/11
QRXQRxPharma Announces A$35 Million Capital Raising
22/07/11PRICE SENSITIVE
QRXInvestor Update and Capital Raising - 20 July 2011
20/07/11
QRXTrading Halt
20/07/11PRICE SENSITIVE
QRXQRxPharma Announces NDA Filing for MoxDuo IR
18/07/11PRICE SENSITIVE
QRXAppendix 3B - Option Issue
13/07/11
QRXAdditional Data on MoxDuo IR Comparative Safety Study
29/06/11PRICE SENSITIVE
QRXInvestor Presentation Update - June 2011
20/06/11
QRXCEO discusses Comparative Safety Study on Boardroom Radio
15/06/11
QRXSuccessful Completion MoxDuo IR Comparative Safety Study
14/06/11PRICE SENSITIVE
QRXPresentation of Clinical Data on MoxDuoTrials at APS Meeting
17/05/11
QRXAppendix 3B - Exercise of Stock Options
13/05/11
QRXAppendix 4C - Quarterly Report 31 March 2011
28/04/11PRICE SENSITIVE
QRXEnrolment of MoxDuo IR Comparative Safety Study Completed
27/04/11PRICE SENSITIVE
QRXUSPTO Issues QRxPharma a New Patent for MoxDuo IR
14/04/11PRICE SENSITIVE
QRXChange in substantial holding
08/04/11
QRXChange in substantial holding
07/04/11
QRXQRxPharma on Track to File New Drug Application Mid-Year
28/03/11PRICE SENSITIVE
QRXCeasing to be a substantial holder
16/03/11
ACL +SandP Announces March SP/ASX Rebalance
04/03/11
QRXHalf Yearly Report and Accounts -31 December 2010
21/02/11PRICE SENSITIVE
QRXInvestor Presentation Update - February 2011
21/02/11
QRXSuccessful Completion Third Pivotal MoxDuo IR Phase 3
21/02/11PRICE SENSITIVE
QRXAppendix 4C - 31 December 2010
27/01/11PRICE SENSITIVE
QRXInitiation of Phase 3 Comparative Safety Study of MoxDuo IR
24/01/11PRICE SENSITIVE
QRXAppendix 3B - Option Issue
06/01/11
QRXQRxPharma Securities Trading Policy
31/12/10
QRXEnrolment of Pivotal MoxDuo IR Phase 3 Study Completed
06/12/10PRICE SENSITIVE
QRXChange of Director's Interest Notice - Peter Campbell
26/11/10
refresh Created with Sketch. REFRESH
 

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Leo Lithium locks in US$116.3M with sale of Goulamina stake to Ganfeng Leo Lithium has revealed it's set for a cash injection with the sale of its interest in the Goulamina Lithium Project (GLP) to Ganfeng.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.